- by Garima Mohta
- 03rd Nov 2020
Have you Checked all the Bank's Name Stocks Which are to be Picked by YES Securities?
Experts to adopt a new strategy in the market after the wait and watch mode to see how the aforementioned events play out. Since last week, Indian indices lost over 2 per cent amid weak global cues. Due to rising COVID-19 cases in Europe and the US, the upcoming US Presidential Election and lack of fiscal stimulus kept the investors on the edge.
Despite the directionless trade, YES Securities is bullish on these 10 stocks:
1. Nippon Life Asset Management:
Rating: Buy | LTP: Rs 271 | Target: Rs 364 | Upside: 34 percent | Q2 FY21 results were in line with estimates. The broking house remains positive on the stock considering expectations of strong equity market performance, NAM gaining market share under the new promoters, costs control will narrow down the financial performance gap when compared with peers, and valuations are attractive at 21.6x FY23E earnings. The estimates for FY21 have been raised by 10 per cent mainly on the back of higher other income.
2. M&M Financial Services:
Rating: LTP: Rs 122 | Target: Rs 175 | Upside: 43 per cent | The broking firm almost retain earnings estimates for FY21/22 and reiterated their positive stance on the stock. Given procyclicality of the franchise, significant management overlay on ECL provisions, healthy capitalisation post rights issue and the worst of growth, credit cost & liquidity conditions behind, it estimates earnings and returns ratios to bounce back strongly from FY22. Despite embedding much higher than regulatory provisioning on the potential restructuring pool, Yes Securities expect MMFS to deliver average RoA of 2.2-2.3% over FY21-22.
3. ICICI Prudential Life:
Rating: Buy | LTP: Rs 403 | Target: Rs 537 | Upside: 33 percent.
YES, Securities is positive on ICICI Pru Life, given its strong delivery in terms of VNB margins (highest amongst listed peers). With benefits of base effect (ICICI Bank focusing only on protection, annuities and ULIPs from Jan 2020), APE growth should come back from Q4 FY21. Valuations are attractive at FY22E P/EV of 2x.
4. SBI Life Insurance:
Rating: Buy | LTP: Rs 769 | Target: Rs 1,006 | Upside: 31 percent |
The broking house remains positive on SBI Life with consistent performance on the protection business and revival in the ULIP business. It continues to focus on extracting more from its bancassurance and agency channels. Limited presence on the online platforms, however, is a dampener. The stock trades at FY22E P/EV of 2.1x, which YES Securities find attractive. It maintained estimates and recommended buy with a one-year price target of Rs 1,006.
5. Kotak Mahindra Bank:
| Rating: Buy | LTP: Rs 1547 | Target: Rs 1,670 | Upside: 8 percent |
YES, Securities raiseD FY21/22 earnings and ABV estimates by 10-12% and 2.5-3% respectively on the back of material upgrade in PPOP expectations (higher NII and lower cost growth now) and a significant reduction in credit cost assumption. It estimates the stand-alone bank to deliver 20-22% earnings CAGR on a 6-7% loan CAGR over FY20-22 because of expansion in core PPOP margin.
6. Torrent Pharma:
| Rating: Buy | LTP: Rs 2,566 | Target: Rs 3,200 | Upside: 24 percent |
The domestic market will increasingly reward players with larger brands. The torrent will maintain the growth of big bands like Shelcal and Losar which will continue to gain share. Margins can surprise on the upside as MR productivity to touch Rs 1million per MR per month; current revenues per MR already one of the highest in industry.
7. Polycab India:
| Rating: Buy | LTP: Rs 920 | Target: Rs 1,118 | Upside: 21 percent |
YES, Securities maintainED positive stance on Polycab post the Q2 results. The sturdy performance reported by the company in Q2 despite the challenges witnessed by the industry is quite encouraging. It believes the company would be able to gain market share in the FMEG segment as it keeps on investing in increasing reach, brand visibility and into new products. Polycab’s robust balance sheet and strong brand recall would allow it to invest in this business (R&D and A&P) and would accelerate market share gains in the FMEG space.
8. RBL Bank:
| Rating: Buy | LTP: Rs 174 | Target: Rs 230 | Upside: 32 percent |
Capping of potential losses in the high-risk businesses of Cards and MFIs, improvement in rating profile and less vulnerability of the corporate portfolio and impressive handle over cost leads us to upgrade earnings estimates (10-13% for FY21/22) and rating (from adding to buy) on the stock, YES Securities said.
9. Axis Bank:
| Rating: Buy | LTP: Rs 492 | Target: Rs 586 | Upside: 19 percent|
YES, Securities retained buy on Axis Bank underpinned by earnings/BV upgrade. Earnings have been revised upwards by lifting NIM and core fee growth assumptions. Considering management’s assessment of probable restructuring pool and encouraging collection trends (demand resolution at 97% in Oct), the brokerage believes that downside risks to their prevailing credit cost estimates have diminished.
10. Dr Reddys’ Laboratories:
| Rating: Add | LTP: Rs 4,888 | Target: Rs 5,270 | Upside: 8 percent |
Traction in the US can persist on back of 30 launches in FY21 and niche/complex launches beyond next fiscal, healthy growth in Europe and other geographies. India business will benefit from COVID drugs in FY21, albeit export markets will continue to be the key driver of revenues and reason behind margin sustaining 25-26% in FY22.
